These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 25429057)

  • 1. Induced pluripotent stem cells from human revertant keratinocytes for the treatment of epidermolysis bullosa.
    Umegaki-Arao N; Pasmooij AM; Itoh M; Cerise JE; Guo Z; Levy B; Gostyński A; Rothman LR; Jonkman MF; Christiano AM
    Sci Transl Med; 2014 Nov; 6(264):264ra164. PubMed ID: 25429057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A "late-but-fitter revertant cell" explains the high frequency of revertant mosaicism in epidermolysis bullosa.
    van den Akker PC; Pasmooij AMG; Joenje H; Hofstra RMW; Te Meerman GJ; Jonkman MF
    PLoS One; 2018; 13(2):e0192994. PubMed ID: 29470523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural gene therapy may occur in all patients with generalized non-Herlitz junctional epidermolysis bullosa with COL17A1 mutations.
    Pasmooij AM; Nijenhuis M; Brander R; Jonkman MF
    J Invest Dermatol; 2012 May; 132(5):1374-83. PubMed ID: 22318390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pigmentation and melanocyte supply to the epidermis depend on type XVII collagen.
    Gostyński A; Pasmooij AM; Del Rio M; Diercks GF; Pas HH; Jonkman MF
    Exp Dermatol; 2014 Feb; 23(2):130-2. PubMed ID: 24330315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3.
    Pasmooij AM; Pas HH; Bolling MC; Jonkman MF
    J Clin Invest; 2007 May; 117(5):1240-8. PubMed ID: 17476356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful therapeutic transplantation of revertant skin in epidermolysis bullosa.
    Gostyński A; Pasmooij AM; Jonkman MF
    J Am Acad Dermatol; 2014 Jan; 70(1):98-101. PubMed ID: 24176523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetically corrected iPSCs as cell therapy for recessive dystrophic epidermolysis bullosa.
    Wenzel D; Bayerl J; Nyström A; Bruckner-Tuderman L; Meixner A; Penninger JM
    Sci Transl Med; 2014 Nov; 6(264):264ra165. PubMed ID: 25429058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple correcting COL17A1 mutations in patients with revertant mosaicism of epidermolysis bullosa.
    Pasmooij AM; Pas HH; Deviaene FC; Nijenhuis M; Jonkman MF
    Am J Hum Genet; 2005 Nov; 77(5):727-40. PubMed ID: 16252234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revertant mosaicism due to a second-site mutation in COL7A1 in a patient with recessive dystrophic epidermolysis bullosa.
    Pasmooij AM; Garcia M; Escamez MJ; Nijenhuis AM; Azon A; Cuadrado-Corrales N; Jonkman MF; Del Rio M
    J Invest Dermatol; 2010 Oct; 130(10):2407-11. PubMed ID: 20574443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revertant mosaicism in the skin.
    Lai-Cheong JE; McGrath JA
    G Ital Dermatol Venereol; 2013 Feb; 148(1):73-82. PubMed ID: 23407079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revertant mosaicism: partial correction of a germ-line mutation in COL17A1 by a frame-restoring mutation.
    Darling TN; Yee C; Bauer JW; Hintner H; Yancey KB
    J Clin Invest; 1999 May; 103(10):1371-7. PubMed ID: 10330419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Keratinocytes from patients lacking collagen XVII display a migratory phenotype.
    Tasanen K; Tunggal L; Chometon G; Bruckner-Tuderman L; Aumailley M
    Am J Pathol; 2004 Jun; 164(6):2027-38. PubMed ID: 15161638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The development of induced pluripotent stem cell-derived mesenchymal stem/stromal cells from normal human and RDEB epidermal keratinocytes.
    Nakayama C; Fujita Y; Matsumura W; Ujiie I; Takashima S; Shinkuma S; Nomura T; Abe R; Shimizu H
    J Dermatol Sci; 2018 Sep; 91(3):301-310. PubMed ID: 29933899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion.
    Jonkman MF; Scheffer H; Stulp R; Pas HH; Nijenhuis M; Heeres K; Owaribe K; Pulkkinen L; Uitto J
    Cell; 1997 Feb; 88(4):543-51. PubMed ID: 9038345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of integration-free induced pluripotent stem cells from human recessive dystrophic epidermolysis bullosa keratinocytes.
    Matsumura W; Fujita Y; Nakayama C; Shinkuma S; Suzuki S; Nomura T; Abe R; Shimizu H
    J Dermatol Sci; 2018 Mar; 89(3):263-271. PubMed ID: 29229433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autosomal dominant junctional epidermolysis bullosa.
    Almaani N; Liu L; Dopping-Hepenstal PJ; Lovell PA; Lai-Cheong JE; Graham RM; Mellerio JE; McGrath JA
    Br J Dermatol; 2009 May; 160(5):1094-7. PubMed ID: 19120338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of functional multipotent keratinocytes from mouse induced pluripotent stem cells.
    Bilousova G; Roop DR
    Methods Mol Biol; 2013; 961():337-50. PubMed ID: 23325655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of interaction between plectin and type XVII collagen results in epidermolysis bullosa simplex.
    Natsuga K; Nishie W; Nishimura M; Shinkuma S; Watanabe M; Izumi K; Nakamura H; Hirako Y; Shimizu H
    Hum Mutat; 2017 Dec; 38(12):1666-1670. PubMed ID: 28941359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous mosaicism: right before our eyes.
    Frank J; Happle R
    J Clin Invest; 2007 May; 117(5):1216-9. PubMed ID: 17476352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of keratinocytes from normal and recessive dystrophic epidermolysis bullosa-induced pluripotent stem cells.
    Itoh M; Kiuru M; Cairo MS; Christiano AM
    Proc Natl Acad Sci U S A; 2011 May; 108(21):8797-802. PubMed ID: 21555586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.